Alopexx, Inc.

expected

Not yet set

status

Filed with SEC

Industry

Biological Products, (No Diagnostic Substances)

Headquarters

United States

Underwriters (from filing)

ThinkEquity LLC

Overview

— AI-generated from the filing, see note below

Business overview

Alopexx, Inc. is a clinical stage biotechnology company focused on developing immune therapeutics targeting poly N-acetyl glucosamine (PNAG) for the prevention and treatment of infections caused by bacterial, fungal, and parasitic pathogens. Their lead product candidates include a vaccine (AV0328) and a monoclonal antibody (F598), both of which have shown promise in early clinical trials for being well tolerated and effective in inducing immune responses against PNAG-expressing pathogens. The company aims to establish therapies that not only target infectious diseases but potentially address neurological conditions as well.

Revenue model

Not disclosed in the provided filing text.

Competitive strengths

Development of broad-spectrum immune therapeutics targeting PNAG.
First-in-man trials indicate well tolerated products with no serious adverse events.
Potential applications beyond infectious diseases, including neurological conditions.

Risk factors

Limited operating history and no products approved for sale.
Anticipate ongoing substantial net losses.
Doubts about continuing as a going concern due to funding needs.
Dependence on the success of AV0328 and F598 for business viability.
Highly competitive landscape with larger competitors.
Reliance on third-party manufacturing and potential regulatory hurdles for product approval.
Long development times for FDA approvals may introduce delays.

Use of proceeds

Not disclosed in the provided filing text.

This summary is generated automatically from the company's own filing and may contain errors or omissions. It is a reading aid, not a substitute for the filing itself, and it is not advice.

IPO details

Underwriters on the deal include ThinkEquity LLC. Alopexx, Inc. is headquartered in United States. It is classified under Biological Products, (No Diagnostic Substances).

Related IPO lists

Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with Alopexx, Inc..

Biotech IPOs United States IPOs

Embed this company

Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.

Iframe — WordPress / Ghost / Notion / Webflow

<iframe src="https://www.discoveripo.com/embed/alopexx" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="Alopexx, Inc. — DiscoverIPO"></iframe>

Dark by default. For a light background, use https://www.discoveripo.com/embed/alopexx?theme=light as the src instead.

Share image — Substack, email, anywhere

https://www.discoveripo.com/ipo/alopexx/opengraph-image

Attribution text

Alopexx, Inc. IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/alopexx?utm_source=embed&utm_medium=text&utm_campaign=alopexx

Track this IPO

Get emailed when Alopexx, Inc.'s terms, price, or expected date change — no weekly noise, just this company.

Where this data comes from

Registration statement filed with the U.S. Securities and Exchange Commission. Retrieved Aug 17, 2026.

View the original filing on SEC EDGAR →

Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.